AIT Bioscience
AIT Bioscience is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
SPI-62 as a treatment for adrenocorticotropic hormone-dependent Cushing’s syndrome
Sponsor Sparrow Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Participants were enrolled across 13 study sites in the United States, Bulgaria, and Romania.
- Of 32 screened participants, 15 were screen failures, primarily because they did not meet inclusion/exclusion criteria.
- Five global protocol amendments clarified study procedures, eligibility criteria, safety monitoring requirements, and study assessments.
- The reported impact of the pandemic on study conduct and data collection was limited.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A 2-part, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate-to-Severe Pruritus in Adult Subjects with Notalgia Paresthetica
Sponsor Cara Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis
Sponsor Merck Sharp & Dohme LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for AIT Bioscience?
The 2026-10-09 snapshot links AIT Bioscience to 6 distinct CTIS trials. Recorded services include Laboratory services, ADA sample analysis, Pharmogenetic testing, PK analysis, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for AIT Bioscience?
The most frequently recorded therapeutic areas are Haematological Malignancies, Endocrinology, Solid Tumor Oncology, Urology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to AIT Bioscience conducted?
The linked trials record locations in 20 countries, including Spain, France, Italy, Poland, Czechia. These are trial locations, not confirmed office locations or countries where AIT Bioscience delivered services.
What can this page tell me about AIT Bioscience's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under AIT Bioscience. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- AIT Bioscience, LLC